Document Classification

Section Type: RESULTS

Text: Patients treated with adalimumab plus MTX demonstrated significant baseline to Week 104 improvements in HAQ-DI (p < 0. 0001), SF-36 Physical Component Summary (p < 0. 0001), 4 SF-36 domains [physical function (p < 0. 0001), bodily pain (p < 0. 0001), vitality (p = 0. 0139), role limitations-physical (p = 0. 0005)], SF-6D (p = 0. 0152), VAS-PtGA (p < 0. 0001), VAS-pain (p < 0. 0001), FACIT-F (p < 0. 0001), and HUI-3 (p = 0. 0034) scores versus patients treated with MTX monotherapy.